Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07580339 Lexucitug Locally Advanced Rectal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07580339 clinical trial report covering Lexucitug, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07580079 Anakinra (Amgen) Hypoglycemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07580079 clinical trial report covering Anakinra (Amgen), Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07581405 Olanzapine stomach adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07581405 clinical trial report covering Olanzapine, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07582159 Tafasitamab-Cxix Chronic Lymphocytic Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07582159 clinical trial report covering Tafasitamab-Cxix, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07582172 Fludarabine Phosphate Relapsing acute myeloid leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07582172 clinical trial report covering Fludarabine Phosphate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600124567 Envafolimab Locally Advanced Gastric Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
ChiCTR2600124567 clinical trial report covering Envafolimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600124522 Nimotuzumab Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
ChiCTR2600124522 clinical trial report covering Nimotuzumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07583511 Serplulimab Extensive stage Small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07583511 clinical trial report covering Serplulimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600124533 Fruquintinib HRD-positive Ovarian Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
ChiCTR2600124533 clinical trial report covering Fruquintinib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07583550 Etoposide Extensive stage Small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07583550 clinical trial report covering Etoposide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07584083 Anifrolumab-FNIA Antiphospholipid Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07584083 clinical trial report covering Anifrolumab-FNIA, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07585513 Mirabegron Postural Orthostatic Tachycardia Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07585513 clinical trial report covering Mirabegron, Phase 2, endpoints, sponsor, geography, readout timing and development white space.